Evidence map›Paper›PMID 42657270›Full record

ArticleiScience2026

Global genetic modifiers of fetal hemoglobin in sickle cell disease: Systematic review and meta-analysis.

Nandini Shende, Shreyasi Athalye, Samriddhi Kamath, Priya Rani, Manisha Madkaikar, Anindita Banerjee, Naveen Khargekar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Nandini ShendeICMR-National Institute of Immunohematology, Mumbai, Maharashtra 400 012, India.
Shreyasi AthalyeICMR-National Institute of Immunohematology, Mumbai, Maharashtra 400 012, India.
Samriddhi KamathICMR-National Institute of Immunohematology, Mumbai, Maharashtra 400 012, India.
Priya RaniICMR- Centre for Research, Management and Control of Hemoglobinopathies, Chandrapur, Mumbai, Maharashtra 442 406, India.
Manisha MadkaikarICMR-National Institute of Immunohematology, Mumbai, Maharashtra 400 012, India.
Anindita BanerjeeICMR-National Institute of Immunohematology, Mumbai, Maharashtra 400 012, India.
Naveen KhargekarICMR-National Institute of Immunohematology, Mumbai, Maharashtra 400 012, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fetal hemoglobin (Hb F) is the strongest endogenous modifier of sickle cell disease (SCD) severity, but its genetic regulation varies across populations. This review synthesized evidence on genetic determinants of Hb F and quantified effects of key variants through meta-analysis. Following PRISMA 2020 guidelines (PROSPERO: CRD420251042025), MEDLINE, EMBASE, Scopus, and Web of Science were searched through May 2026. Studies evaluating genetic associations with Hb F levels in SCD were included. Narrative synthesis and random-effects meta-analysis were performed. Eighty-four studies identified 80 variants across 32 genes associated with Hb F levels. The most consistently replicated associations involved

Indexed as

fetal hemoglobin levelsgenetic modifiersickle cell disease

Identifiers

PMID42657270
PMCPMC13508651

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.